Dr. Hallam brings a broad base of pharmaceutical expertise, having led virtually every stage of pre-clinical research and clinical development. Prior to joining Leading BioSciences, he served as Director of Therapeutic Programs and Head of New Product Development for Mesoblast Inc., directing commercialization strategy and product development of adult stem cell products. He previously served in the San Francisco office of C1 Consulting, helping pharmaceutical companies launch and commercialize new products, and previously served as Medical Director at Saatchi & Saatchi Healthcare in New York, responsible for leading the healthcare professional marketing strategy team that was honored as “The Best Large Marketing Team of 2010” by Medical Marketing and Media Magazine. Past experience also includes leading the pharmacology group at Helicon Therapeutics, where he directed research operations at four U.S. locations and managed global CRO operations. Over the course of his career, he has successfully advanced eight drugs from pre-clinical research to Phase 2 trials and played a major role in 28 clinical studies, with demonstrating efficacy in 92% of those studies. He understands how to design clinical studies to maximize data for regulatory approval, business development and marketing. He has served as an adviser to 19 of the world’s leading healthcare companies, including Roche/Genentech, Pfizer, Sanofi, Astra-Zeneca, and Bausch & Lomb. Dr. Hallam is a former Howard Hughes Medical Institute Research fellow. He received his Ph.D. in neuroscience from University California, Davis and holds an MBA from University of Southern California.